n this episode, the OMA Chief Science Officer, Dr. Harold Bays, FOMA Dipl. ABOM interviews Dr. William McCarthy, FOMA about a recent article discussing changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia. Topics covered include: awareness of medications that cause weight gain for patients with obesity, why individual treatment strategies are key when considering medications that may be weight positive as each patient may respond differently, and the importance of communication between medical providers in following patient progress to avoid complications.
In our article review podcasts, we have carefully selected recent articles included in the latest version of the Obesity Medicine Association (OMA) Obesity Algorithm. We then discuss this new science with obesity experts.
To access other resources from the clinical leader in Obesity Medicine, visit: www.obesitymedicine.org.
- Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies.